We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Elevated Fructosamine Levels Associated with Increased PJI Risk

By LabMedica International staff writers
Posted on 24 Nov 2020
Periprosthetic joint infection (PJI) is the most serious complication that lowers the quality of patients’ life by elevating the patients’ burden of cost and affecting the outcome of total joint arthroplasty. More...


The fructosamine test is a measurement of glycated protein, mainly albumin (the main protein in the blood). When glucose levels in the blood are elevated over a period of time, glucose molecules permanently combine with proteins in the blood in a process called glycation.

Clinical scientists at the Rothman Orthopaedic Institute (Orlando, FL, USA) evaluated in a prospective multi-institutional study preoperative fructosamine and HbA1c levels in patients who had elective total hip arthroplasty (THA) from November 2017 to August 2018. The total patient cohorts included 1,212 patients and patients with and without diabetes were enrolled. The teams assessed fructosamine and HbA1c levels two to three weeks preoperatively. Adverse outcomes, such as PJI, wound complications, readmission and mortality, were assessed at one year postoperatively. A fructosamine level greater than 293 mol/L was defined as inadequate glycemic control and as a predictor for adverse outcomes.

Overall, 960 patients were available for follow-up at 1 year, at which time 3.5% of patients showed inadequate glycemic control based on fructosamine value. This was an unexpected finding as among patients with elevated fructosamine, 85% were unaware they had pre-diabetes and 42% were unaware they had diabetes. The PJI and mortality rates were six times higher in patients with high fructosamine. Readmission rates were five times higher in patients with high fructosamine. Patients with high fructosamine groups had PJI rates of almost 10% and readmission rates of 16%.

Noam Shohat, MD, an orthopedic surgeon and lead author of the study, said, “Fructosamine is inexpensive and readily available marker. It is better reflects the glucose levels prior to surgery. So, it is a better reflector and predictor of outcomes and responds quicker to treatment. For those with levels above 293 mol/L, we strongly encourage you to reconsider the need for surgery.”

The authors concluded that the association between high fructosamine levels and increased risk for PJI was statistically significant after adjustment for age, comorbidities and preoperative HbA1c levels in a regression analysis. The study was presented at the American Association of Hip and Knee Surgeons Annual Hybrid Meeting held November 5-8, 2020 in Dallas, TX, USA.

Related Links:
Rothman Orthopaedic Institute


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.